Clinical trials: Large B Cell Lymphoma
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
This randomized phase II trial studies how well rituximab and combination chemotherapy with or without lenalidomide work in treating patients with newly diagnosed stage II-IV diffuse large B cell lymphoma.
- Conditions
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
- Trial name
- NCT01856192
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- 502 sites in United States
- Volunteers
- 349 people
- Sponsor
- National Cancer Institute (NCI)
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
This phase I trial studies the side effects and best dose of cellular immunotherapy following chemotherapy in treating patients with non-Hodgkin lymphomas, chronic lymphocytic leukemia, or B-cell prolymphocytic leukemia that has…
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, High Grade B-Cell Lymphoma, Not Otherwise Specified, Post-Transplant Lymphoproliferative Disorder
- Trial name
- NCT02153580
- Testing
- Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- City of Hope Medical Center
ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
This phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have come back (recurrent) or do not respond to treatment (refractory).
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- Trial name
- NCT03038672
- Testing
- Nivolumab, Varlilumab
- Where
- 33 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
This phase II/III trial tests whether it is possible to decrease the chance of high-grade B-cell lymphomas returning or getting worse by adding a new drug, venetoclax to the usual combination of drugs used for treatment.
- Conditions
- Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT03984448
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 634 sites in United States
- Volunteers
- 363 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis.
- Conditions
- Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL, NHL
- Trial name
- NCT04002947
- Testing
- DA-EPOCH, Rituximab, CHOP
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).
- Conditions
- Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04545762
- Testing
- Fludarabine, Cyclophosphamide, anti-CD19 CAR-T cells
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- C. Babis Andreadis
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This phase I trial evaluates the best dose, possible benefits and/or side effects of fludarabine and cyclophosphamide with or without rituximab before CD19 chimeric antigen receptor T cells in treating patients with diffuse large…
- Trial name
- NCT05052528
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, Davis
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a…
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Trial name
- NCT06015880
- Testing
- Biospecimen Collection, Computed Tomography, Lenalidomide
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT06533579
- Testing
- Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Vironexis Biotherapeutics Inc.
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 Injection for patients with diffuse large B-cell lymphoma.
- Trial name
- NCT07260812
- Testing
- KSV01 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- TCRx Therapeutics Co.Ltd
Anaplastic Large Cell Lymphoma
BV-CHP Real-life and Biological Evidences in Patients With sALCL
Systemic Anaplastic Large Cell Lymphomas (sALCL) are rare lymphomas for which the cooperation in the collection of biological and clinical data is necessary to improve knowledge on the disease.
- Trial name
- FIL_BREAL (NCT07467317)
- Where
- 19 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Relapsed or Refractory Large B-cell Lymphoma
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy.
- Trial name
- NCT07479797
- Testing
- KITE-753, Axicabtagene Ciloleucel, Fludarabine
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 550 people
- Sponsor
- Kite, A Gilead Company
Lymphoma, Non-Hodgkin, Lymphoma, Follicular
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL.
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
- Trial name
- WaveSpan-008 (NCT07519772)
- Testing
- MK-1045
- Where
- 49 sites in United States, Argentina and 13 more
- Volunteers
- 280 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
This is a clinical trial to evaluate the safety of combining CAR T-cell therapy with low-dose total body irradiation (LD-TBI) in patients with previously treated large B-cell lymphoma (LBCL) or multiple myeloma (MM).
- Trial name
- Prime REMIX (NCT07725406)
- Testing
- Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Weill Medical College of Cornell University
Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
RATIONALE: Biological therapies, such as fusion protein cytokine therapy, may stimulate the immune system in different ways and stop cancer cells from growing.
- Conditions
- Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma
- Trial name
- NCT00720135
- Testing
- DI-Leu16-IL2 immunocytokine, rituximab, flow cytometry
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- City of Hope Medical Center
Lymphoma, Large B-cell, Diffuse
30Gy Versus 40Gy Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy
The purpose of this study is to determine whether 30Gy radiotherapy is as effective as 40Gy in the treatment of localized Diffused Large B cell Lymphoma (DLBCL) when completing CR after chemotherapy.
- Trial name
- NCT01156259
- Testing
- Radiotherapy followed by chemotherapy, 3D-CRT based Involved Field Radiotherapy
- Where
- China
- Volunteers
- 432 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-Hodgkin Lymphoma, Burkitt Lymphoma
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this…
- Conditions
- Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma
- Trial name
- O-ICE (NCT02393157)
- Testing
- Obinutuzumab, Liposomal ARA-C, Ifosfamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York Medical College
Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP.
- Conditions
- Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT03147885
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Diffuse Large B-Cell Lymphoma
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy.
- Trial name
- EPCORE DLBCL-3 (NCT05660967)
- Testing
- Epcoritamab, Lenalidomide
- Where
- 74 sites in United States, Austria and 10 more
- Volunteers
- 111 people
- Sponsor
- Genmab
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression
Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study
Treatment for blood cancers has improved significantly, and more patients are now living longer. However, these treatments are often intensive and long-lasting, and many patients experience serious side effects and symptoms.
- Conditions
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression, Multiple Myeloma Refractory
- Trial name
- NCT07634263
- Where
- 3 sites in Denmark
- Volunteers
- 50 people
- Sponsor
- Odense University Hospital